XLON
NFX
Market cap2mUSD
May 30, Last price
0.11GBP
1D
-6.38%
1Q
22.22%
IPO
-96.00%
Name
Nuformix PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.30%
Rev. gr., 5y
277.98%
Revenues
0k
Net income
-4m
L+535.54%
CFO
-332k
L-39.24%
Earnings
Jun 16, 2025
Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑07 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | 577 | 819 | |||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (577) | (819) | |||||||||
NOPBT Margin | |||||||||||
Operating Taxes | 6 | (46) | |||||||||
Tax Rate | |||||||||||
NOPAT | (583) | (773) | |||||||||
Net income | (3,641) | (573) -48.33% | |||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 150 | 285 | 228 | ||||||||
BB yield | -32.48% | -15.22% | |||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | (20) | (203) | (259) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (332) | (546) | (433) | ||||||||
CAPEX | |||||||||||
Cash from investing activities | 33 | ||||||||||
Cash from financing activities | 150 | 190 | 228 | ||||||||
FCF | (402) | (650) | 138 | ||||||||
| Balance | |||||||||||
Cash | 20 | 203 | 259 | ||||||||
Long term investments | |||||||||||
Excess cash | 20 | 203 | 259 | ||||||||
Stockholders' equity | (9,025) | (2,462) | (7,401) | ||||||||
Invested Capital | 9,741 | 6,657 | 11,629 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 786,932 | 719,462 | |||||||||
Price | 0.00 -81.13% | 0.00 -73.33% | 0.00 -68.21% | ||||||||
Market cap | 460 | 1,871 -67.94% | |||||||||
EV | 440 | 1,668 | |||||||||
EBITDA | (548) | (782) | 37 | ||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||